Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Wilkin

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
AIDS Research and Human Retroviruses|February 20, 2018
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear CellsDominique B Figueroa, Erin P Madeen, Joseph Tillotson, et al.
HIV Clinical Trials|April 25, 2013
High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccineTimothy Wilkin, Jeannette Y Lee, Shelly Y Lensing, et al.
Open Forum Infectious Diseases|March 22, 2019
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized TrialJonathan Z Li, Paul E Sax, Vincent C Marconi, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2016
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H Borges, Jacqueline Neuhaus, Abdel G Babiker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2018
A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium TrialStephen E Goldstone, Shelly Y Lensing, Elizabeth A Stier, et al.
Annals of Internal Medicine|November 24, 2015
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled TrialKaren T Tashima, Laura M Smeaton, Carl J Fichtenbaum, et al.
The Journal of Infectious Diseases|September 4, 2010
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected menTimothy Wilkin, Jeannette Y Lee, Shelly Y Lensing, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 3, 2018
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized TrialBabafemi O Taiwo, Vincent C Marconi, Baiba Berzins, et al.
Lancet (London, England)|April 10, 2007
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsBonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
AIDS Research and Human Retroviruses|February 20, 2018
Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear CellsDominique B Figueroa, Erin P Madeen, Joseph Tillotson, et al.
HIV Clinical Trials|April 25, 2013
High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccineTimothy Wilkin, Jeannette Y Lee, Shelly Y Lensing, et al.
Open Forum Infectious Diseases|March 22, 2019
No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized TrialJonathan Z Li, Paul E Sax, Vincent C Marconi, et al.
JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2016
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H Borges, Jacqueline Neuhaus, Abdel G Babiker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2018
A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium TrialStephen E Goldstone, Shelly Y Lensing, Elizabeth A Stier, et al.
Annals of Internal Medicine|November 24, 2015
HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled TrialKaren T Tashima, Laura M Smeaton, Carl J Fichtenbaum, et al.
The Journal of Infectious Diseases|September 4, 2010
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected menTimothy Wilkin, Jeannette Y Lee, Shelly Y Lensing, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 3, 2018
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized TrialBabafemi O Taiwo, Vincent C Marconi, Baiba Berzins, et al.
Lancet (London, England)|April 10, 2007
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsBonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, et al.
Pageof 6